Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor

Biochemical and Biophysical Research Communications

Volumn 434, Issue 3, 2013, Pages 413-420

  Fujii, Seiko ^a   Okinaga, Toshinori ^a   Ariyoshi, Wataru ^a   Takahashi, Osamu ^a   Iwanaga, Kenjiro ^a   Nishino, Norikazu ^a   Tominaga, Kazuhiro ^a   Nishihara, Tatsuji ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Apoptosis; Cell cycle; Histone deacetylase inhibitor; Myeloma cell

Indexed keywords

CASPASE 9; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; KY 2; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; G1 PHASE CELL CYCLE CHECKPOINT; HISTONE ACETYLATION; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRYPAN BLUE ASSAY; WESTERN BLOTTING; WST ASSAY; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL CYCLE G1 PHASE; FEMALE; FLOW CYTOMETRY; HUMAN; MULTIPLE MYELOMA; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; G1 PHASE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA;

MLCS; MLOWN;

EID: 84880475894     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.043     Document Type: Article

References (35)

1. L. Mileshkin, J.J. Biagi, P. Mitchell, C. Underhil, A. Grigg, R. Bell, et al., Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age, Blood 102 (2003) 69-77.
2. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, et al., A phase 2 study of bortezomib in relapsed, refractory myeloma, N. Engl. J. Med. 348 (2003) 2609-2617.
3. N.C. Munshi, G. Tricot, R. Desikan, A. Badros, M. Zangari, A. Toor, et al., Clinical activity of arsenic trioxide for the treatment of multiple myeloma, Leukemia 16 (2002) 1835-1837.
4. P.P. Pandolfi, Histone deacetylases and transcriptional therapy with their inhibitors, Cancer Chemother. Pharmacol. 48 (2001) 17-19.
5. O.H. Kramer, M. Gottlicher, T. Heinzel, Histone deacetylase as a therapeutic target, Trends Endocrinol. Metab. 12 (2001) 294-300.
6. P. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, W.K. Kelly, Histone deacetylases and cancer: causes and therapies, Nat. Rev. Cancer 1 (2001) 194-202.
7. R. Brown, G. Strathdee, Epigenomics and epigenetic therapy of cancer, Trends Mol. Med. 8 (2002) 43-48.
8. R.X. Luo, D.C. Dean, Chromatin remodeling and transcriptional regulation, J. Natl. Cancer Inst. 91 (1999) 1288-1294.
9. R. Furumai, Y. Komatsu, N. Nishino, S. Khochbin, M. Yoshida, S. Horinouchi, Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin, Proc. Natl. Acad. Sci. USA 98 (2001) 87-92.
10. A. Peserico, C. Simone, Physical and functional HAT/HDAC interplay regulates protein acetylation balance, J. Biomed. Biotechnol. (2011), http://dx.doi.org/ 10.11155/2011/371832.
11. K.B. Glaser, Defining the role of gene regulation in resistance to HDAC inhibitors-mechanisms beyond P-glycoprotein, Leuk. Res. 30 (2006) 651-652.
12. C.Y. Gui, L. Ngo, W.S. Xu, V.M. Richon, P.A. Marks, Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1, Proc. Natl. Acad. Sci. USA 101 (2004) 1241-1246.
13. R.W. Johnstone, Histone-deacetylase inhibitors: novel drugs for the treatment of cancer, Nat. Rev. Drug Discov. 1 (2002) 287-299.
14. N. Nishino, B. Jose, R. Shinta, T. Kato, Y. Komatsu, M. Yoshida, Chlamydocinhydroxamic acid analogues as histone deacetylase inhibitors, Bioorg. Med. Chem. 12 (2004) 5777-5784.
15. L.C. Sambucetti, D.D. Fischer, S. Zabludoff, P.O. Kwon, H. Chamberlin, N. Trogani, et al., Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects, J. Biol. Chem. 274 (1999) 34940-34947.
16. D. Lavelle, Y.H. Chen, M. Hankewych, J. DeSimone, Histone deacetylase inhibitors increase p21 (WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression, Am. J. Hematol. 68 (2001) 170-178.
17. T. Koseki, K. Yamato, S. Krajewski, J.C. Reed, Y. Tsujimoto, T. Nishihara, Activin A-induced apoptosis is suppressed by BCL-2, FEBS Lett. 376 (1995) 247-250.
18. T. Nishihara, Y. Ohsaki, N. Ueda, T. Koseki, Y. Eto, Induction of apoptosis in B lineage cells by activin A derived from macrophages, J. Interferon Cytokine Res. 15 (1995) 509-516.
19. K. Halkidou, L. Gaughan, S. Cook, H.Y. Leung, D.E. Neal, C.N. Robson, Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer, Prostate 59 (2004) 177-189.
20. B.H. Huang, M. Laban, C.H. Leung, L. Lee, C.K. Lee, M. Salto-Tellez, et al., Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1, Cell Death Differ. 12 (2005) 395-404.
21. J. Song, J.H. Noh, J.H. Lee, J.W. Eun, Y.M. Ahn, S.Y. Kim, et al., Increased expression of histone deacetylase 2 is found in human gastric cancer, APMIS 113 (2005) 264-268.
22. A. Hrzenjak, F. Moinfar, M.L. Kremser, B. Strohmeier, P.B. Staber, K. Zatloukal, et al., Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells, Mol. Cancer Ther. 5 (2006) 2203-2210.
23. K. Kitazoe, M. Abe, M. Hiasa, A. Oda, H. Amou, T. Harada, et al., Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma, Int. J. Hematol. 89 (2009) 45-57.
24. R. Somech, S. Izraeli, S.J. Simon, Histone deacetylase inhibitors-a new tool to treat cancer, Cancer Treat. Rev. 30 (2004) 461-472.
25. J. Kikuchi, T. Wada, R. Shimizu, T. Izumi, M. Akutsu, K. Mitsunaga, et al., Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma, Blood 116 (2010) 406-417.
26. Y. Komatsu, K.Y. Tomizaki, M. Tsukamoto, T. Kato, N. Nishino, S. Sato, et al., Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity, Cancer Res. 61 (2001) 4459-4466.
27. F. McLaughlin, N.B. La Thangue, Histone deacetylase inhibitors open new doors in cancer therapy, Biochem. Pharmacol. 68 (2004) 1139-1144.
28. R.A. Weinberg, The retinoblastoma protein and cell cycle control, Cell 81 (1995) 323-330.
29. H. Matsushime, M.F. Roussel, R.A. Ashmun, C.J. Sherr, Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle, Cell 65 (1991) 701-713.
30. V. Sandor, A. Senderowicz, S. Mertins, D. Sackett, E. Sausville, M.V. Blagosklonny, et al., P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228, Br. J. Cancer 83 (2000) 817-825.
31. T.E. Fandy, S. Shankar, D.D. Ross, E. Sausville, R.K. Srivastava, Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma, Neoplasia 7 (2005) 646-657.
32. E.A. Slee, M.T. Harte, R.M. Kluck, B.B. Wolf, C.A. Casiano, D.D. Newmeyer, et al., Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner, J. Cell Biol. 144 (1999) 281-292.
33. E.H. Cheng, M.C. Wei, S. Weiler, R.A. Flavell, T.W. Mak, T. Lindsten, et al., BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis, Mol. Cell 8 (2001) 705-711.
34. H. Zou, Y. Li, X. Liu, X. Wang, An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9, J. Biol. Chem. 274 (1999) 11549-11556.
35. J. Yang, X. Liu, K. Bhalla, C.N. Kim, A.M. Ibrado, J. Cai, T.I. Peng, D.P. Jones, X. Wang, Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked, Science 275 (1997) 1129-1132.